Last reviewed · How we verify

NCT07263490: PRIOR

PRIOR Study (Pre-eclampsia Risk In Oocyte Recipients)

Recruiting now Last updated 13 April 2026
What this trial tests

trial in Pre-eclampsia in 462 participants. Currently enrolling.

Timeline
21 October 2024
Primary endpoint
31 October 2027
1 June 2028

Quick facts

Lead sponsorCopenhagen University Hospital, Hvidovre
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment462
Start date21 October 2024
Primary completion31 October 2027
Estimated completion1 June 2028
Sites6 locations across Denmark

Conditions studied

Sponsor

Copenhagen University Hospital, Hvidovre

Who can join

18 and older, female only, with Pre-eclampsia or Oocyte Donation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this prospective observational cohort study is to investigate the pathophysiological mechanisms behind and risk of pre-eclampsia in women pregnant after fertility treatment with oocyte donation. The participants are included in of of two cohorts. One includes women pregnant after oocyte donation whereas the other includes women pregnant after IVF treatment with autologous oocytes. Participants will be followed throughout pregnancy with blood samples, blood pressure, clinical controls and ultrasound examinations. Clinical outcomes will be registered post-partum.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Pre-eclampsia

Currently open trials in the same condition.

Other Copenhagen University Hospital, Hvidovre trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07263490.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing